Dr. Edmund Tsui, MD

Dr. Tsui practices at Peter Morton UCLA Medical Building in Los Angeles, California.

Dr. Tsui's NPI, 1255743712, was assigned on June 2, 2014. Dr. Tsui graduated from Geisel School Of Medicine At Dartmouth in 2014. Dr. Tsui's California license number on file is A155023.

Dr. Tsui's primary practice is Peter Morton UCLA Medical Building, at 200 Medical Plz, Los Angeles, CA 90024 in Los Angeles County. The practice phone is (310) 794-9206.

Dr. Tsui's primary practice is Peter Morton UCLA Medical Building in Los Angeles, California. Dr. Tsui is also affiliated with Ronald Reagan UCLA Medical Center. The medical group on file is UCSF Medical Group. Dmand AI also links Dr. Tsui to 1 more hospital, 2 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tsui practices, 3 sites in all. Vendor and product names are available with a free account.

Uveitis and ocular inflammatory disease is Dr. Tsui's primary specialty in the NPI Registry, under taxonomy code 207WX0108X. Dr. Tsui is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Tsui's licenses on file in 3 states: California, New Hampshire and New York.

Dmand AI lists dry eye, eyelid inflammation, glaucoma, inflammation of iris, scleritis and shingles among the conditions Dr. Tsui treats.

CMS data shows 997 Medicare services from Dr. Tsui across 6 procedure codes in 2024, for 240 Medicare patients. Medicare paid $72,609 for them. Every service was in an office.

CMS counts 240 Medicare patients who saw Dr. Tsui in 2024. The largest group is 65 to 74, with 108 patients. 75% of them have high cholesterol, and 68% have high blood pressure. 22% are also on Medicaid. Their average risk score is 1.34, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Tsui's median patient age at 56, with 65% women.

In 2024, Dr. Tsui wrote 426 Medicare Part D claims for 122 patients. 67% of them were for generic drugs. CMS names the drug for 375 of them, across 8 drugs with 11 or more claims each, at $19,558 in total drug cost. In 2023, CMS named 300 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 86 out of 100 for Dr. Tsui for performance year 2024, reported as part of a group. Dr. Tsui accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Tsui as offering telehealth.

Dmand AI links 28 papers to Dr. Tsui, published from 2011 to 2025. 2025 was the busiest year, with 5. The most frequent topics are Health Expenditures, Hong Kong and Uveitis. Dr. Tsui has published most often in Hong Kong Med J. Dr. Tsui's most frequent co-authors are Sapna S. Gangaputra, CPH, MD, MPH, Jie Deng, MD, PhD and Thuy Doan, MD.

CMS Open Payments shows 57 general payments to Dr. Tsui from 13 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 61% of the total. Genentech, Inc. paid the most, $7,913. It also lists 1 research payment totaling $1,791 in 2025.

Dr. Tsui graduated from Geisel School Of Medicine At Dartmouth in 2014.

Dr. Tsui is in network with 7 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.